SEC Form 4 · accession 0001513162-15-000554

UNILENS VISION INC · UVIC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Sep 2, 2015

Accepted (ET)

Sep 17, 2015 · 5:28 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000852564

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Sep 2, 2015	D	56,950	$12.75	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Buy Common Stock^F3,F2	$7.92	Sep 2, 2015	D	25,000	D	—	Mar 1, 2020	Common Stock	25,000	0	D

F1Pursuant to the terms of the Agreement and Plan of Merger, on July 10, 2015, by and among Valeant Pharmaceuticals International, a Delaware corporation ("Parent"), OneEye Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), and Unilens Vision Inc., a Delaware corporation (the "Issuer"), each share of the Issuer's stock issued and outstanding immediately prior to the Effective Time (as defined in the Agreement and Plan of Merger) was converted into the right to receive $12.75 per share in cash, subject to any applicable withholding taxes.
F2Options are 100% vested.
F3Pursuant to the terms of the Agreement and Plan of Merger, immediately prior to the Effective Time (as defined in the Agreement and Plan of Merger), each unexpired and unexercised option to purchase the Issuer's common stock, all of which were exercisable and vested, was cancelled and, in exchange therefor, each option holder became entitled to receive a cash payment equal to the product of (i) the total number of shares previously subject to such option and (ii) the excess of the merger consideration ($12.75 per share) over the exercise price of the option.